

34. A vaccine according to claim 25, further comprising a non-hepatitis antigen.
35. A vaccine according to claim 29, further comprising a non-hepatitis antigen.
36. A vaccine according to claim 30, further comprising a non-hepatitis antigen.
37. A vaccine according to claim 31, further comprising a non-hepatitis antigen.
38. A vaccine according to claim 32, further comprising a non-hepatitis antigen.
39. A vaccine according to claim 33, further comprising a non-hepatitis antigen.
40. A method of producing a Hepatitis A vaccine, which method comprises mixing a preparation of inactivated Hepatitis A virus according to claim 22 with a pharmaceutically acceptable carrier.


REMARKS

The above-identified application is being entered into the National Phase from PCT application no. PCT/EP99/07765.

Applicants have cancelled claims 1-16 and added new claims 17-40 to put the claims in conformity with U.S. practice.

No new matter has been introduced.

Respectfully submitted,


Zoltan Kerekes
Attorney for Applicants
Registration No. 38,938

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5024
Facsimile (610) 270-5090
N:\zklapps\b45160\Preamd.doc